pyrazines has been researched along with Nervous System Disorders in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S | 1 |
| Vij, R | 1 |
| Hu, X; Tian, M; Wan, H; Yang, J; Zhang, H; Zhao, C; Zhu, H | 1 |
| Berdel, WE; Einsele, H; Gann, CN; Knop, S; Kropff, M; Liebisch, P; Wand, H; Weisel, K | 1 |
| Chott, A; Formanek, M; Hauff, W; Jonak, C; Müllauer, L; Püspök, A; Raderer, M; Troch, M; Zielinski, CC | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Wang, M | 1 |
| Chabrier, PE; Croci, N; Ding-Zhou, L; Marchand-Verrecchia, C; Margaill, I; Palmier, B; Plotkine, M | 1 |
| Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J | 1 |
| Christoph, T; Erdmann, VA; Frank, R; Gillen, C; Grünweller, A; Kurreck, J; Mika, J; Schäfer, MK; Wade, EJ; Weihe, E | 1 |
| Davies, FE; Jenner, M; Morgan, GJ; Saso, R; Srikanth, M; Wu, P | 1 |
| Auguet, M; Chabrier, PE; Demerlé-Pallardy, C | 1 |
2 review(s) available for pyrazines and Nervous System Disorders
| Article | Year |
|---|---|
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism | 2011 |
Nitric oxide synthases: targets for therapeutic strategies in neurological diseases.
Topics: Alzheimer Disease; Amidines; Amyotrophic Lateral Sclerosis; Animals; Benzylamines; Brain Injuries; Brain Ischemia; Enzyme Induction; Humans; Huntington Disease; Mice; Mice, Neurologic Mutants; Mice, Transgenic; Nerve Degeneration; Nerve Tissue Proteins; Nervous System Diseases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Organ Specificity; Polymethacrylic Acids; Pyrazines; Thiophenes | 1999 |
4 trial(s) available for pyrazines and Nervous System Disorders
| Article | Year |
|---|---|
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Remission Induction | 2009 |
A phase II study of bortezomib in patients with MALT lymphoma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nausea; Nervous System Diseases; Pyrazines; Treatment Outcome | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2005 |
6 other study(ies) available for pyrazines and Nervous System Disorders
| Article | Year |
|---|---|
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Protective effect of chuanxiongzine-puerarin in a rat model of transient middle cerebral artery occlusion-induced focal cerebral ischemia.
Topics: Animals; Antioxidants; Brain; Gene Expression Regulation; Glucose; Infarction, Middle Cerebral Artery; Interleukin-1; Ischemic Attack, Transient; Isoflavones; Male; Malondialdehyde; Nervous System Diseases; Neuroprotective Agents; Nitric Oxide; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Superoxide Dismutase; Synaptophysin; Tetrazolium Salts | 2008 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous | 2010 |
Neuroprotective effects of (S)-N-[4-[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl]-1-piperazinyl]phenyl]-2-thiophenecarboximid-amide (BN 80933), an inhibitor of neuronal nitric-oxide synthase and an antioxidant, in model of
Topics: Animals; Antioxidants; Blood-Brain Barrier; Brain Edema; Brain Infarction; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Mice; Nervous System Diseases; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Peroxidase; Pyrazines; Thiophenes | 2003 |
Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
Topics: Animals; Base Sequence; Capsaicin; Chlorocebus aethiops; Colitis; COS Cells; Disease Models, Animal; Humans; Male; Mice; Molecular Sequence Data; Nervous System Diseases; Pain; Pyrazines; Pyridines; Rats; RNA Interference; Sequence Alignment; Sequence Homology, Amino Acid; TRPV Cation Channels | 2006 |
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |